BIOINFORMATICS Russian patent published in 2025 - IPC G01N33/543 G16B30/10 

FIELD: biotechnology.

SUBSTANCE: described is a method for identifying a tumour-specific antigen using the following device, comprising: microfluidic device comprising at least one flow channel containing a plurality of micropillars arranged in a matrix, to which at least one molecule is attached or at least one complex associated with at least one antibody against major histocompatibility complex or at least one antibody against human pan-leukocyte antigen (HLA), whereby peptide: major histocompatibility complex (pMHC) in a sample passing through said channel, can be extracted from said sample using said at least one antibody; and processor adapted to identify said peptide bound to said major histocompatibility complex, and to compare said peptide of said bound pMHC with a library of peptide antigens of pathogens to determine whether said peptide, which is or has been associated with said major histocompatibility complex, homology/affinity with at least one pathogen antigen or part thereof, and where there is more than 60% homology/affinity; determining said peptide, which is or has been linked to said major histocompatibility complex, as a tumour-specific antigen for use in anticancer therapy. Described is a method for patient stratification with respect to cancer treatment with a checkpoint inhibitor. Also disclosed is a method for patient stratification with respect to the treatment of adenoviral cancer. Disclosed is a method of treating cancer.

EFFECT: invention extends the range of anti-cancer agents.

21 cl, 13 dwg, 6 tbl